BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

339 related articles for article (PubMed ID: 32193532)

  • 21. Dysplasia in short-segment Barrett's esophagus: a prospective 3-year follow-up.
    Sharma P; Morales TG; Bhattacharyya A; Garewal HS; Sampliner RE
    Am J Gastroenterol; 1997 Nov; 92(11):2012-6. PubMed ID: 9362182
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Surveillance and follow-up strategies in patients with high-grade dysplasia in Barrett's esophagus: a Dutch population-based study.
    Verbeek RE; van Oijen MG; ten Kate FJ; Vleggaar FP; Schipper ME; Casparie MK; van Baal JW; Siersema PD
    Am J Gastroenterol; 2012 Apr; 107(4):534-42. PubMed ID: 22270082
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Increasing prevalence of high-grade dysplasia and adenocarcinoma on index endoscopy in Barrett's esophagus over the past 2 decades: data from a multicenter U.S. consortium.
    Desai M; Lieberman DA; Kennedy KF; Hamade N; Thota P; Parasa S; Gorrepati VS; Bansal A; Gupta N; Gaddam S; Young PE; Mathur S; Moawad FJ; Cash BD; Sampliner R; Vargo JJ; Falk GW; Sharma P
    Gastrointest Endosc; 2019 Feb; 89(2):257-263.e3. PubMed ID: 30342028
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Influence of body mass index on the prevalence and progression of dysplasia in Barrett's esophagus: a retrospective analysis (.).
    Thota PN; Arora Z; Benjamin T; Pagadala M; Lopez R; Sanaka MR
    Scand J Gastroenterol; 2016 Nov; 51(11):1288-93. PubMed ID: 27460942
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Endoscopic therapy of esophageal premalignancy and early malignancy.
    Nealis TB; Washington K; Keswani RN
    J Natl Compr Canc Netw; 2011 Aug; 9(8):890-9. PubMed ID: 21900219
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Surveillance in Barrett's esophagus: an audit of practice.
    Ajumobi A; Bahjri K; Jackson C; Griffin R
    Dig Dis Sci; 2010 Jun; 55(6):1615-21. PubMed ID: 19669878
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Incidence of Progression of Persistent Nondysplastic Barrett's Esophagus to Malignancy.
    Peters Y; Honing J; Kievit W; Kestens C; Pestman W; Nagtegaal ID; van der Post RS; Siersema PD
    Clin Gastroenterol Hepatol; 2019 Apr; 17(5):869-877.e5. PubMed ID: 30213587
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Barrett Esophagus Length, Nodularity, and Low-grade Dysplasia are Predictive of Progression to Esophageal Adenocarcinoma.
    Solanky D; Krishnamoorthi R; Crews N; Johnson M; Wang K; Wolfsen H; Fleischer D; Ramirez FC; Katzka D; Buttar N; Iyer PG
    J Clin Gastroenterol; 2019; 53(5):361-365. PubMed ID: 29608452
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Risk of progression in Barrett's esophagus indefinite for dysplasia: a systematic review and meta-analysis.
    Krishnamoorthi R; Mohan BP; Jayaraj M; Wang KK; Katzka DA; Ross A; Adler DG; Iyer PG
    Gastrointest Endosc; 2020 Jan; 91(1):3-10.e3. PubMed ID: 31421077
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Advanced pathology under squamous epithelium on initial EMR specimens in patients with Barrett's esophagus and high-grade dysplasia or intramucosal carcinoma: implications for surveillance and endotherapy management.
    Chennat J; Ross AS; Konda VJ; Lin S; Noffsinger A; Hart J; Waxman I
    Gastrointest Endosc; 2009 Sep; 70(3):417-21. PubMed ID: 19555948
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Yield of Repeat Endoscopy in Barrett's Esophagus with No Dysplasia and Low-Grade Dysplasia: A Population-Based Study.
    Visrodia K; Iyer PG; Schleck CD; Zinsmeister AR; Katzka DA
    Dig Dis Sci; 2016 Jan; 61(1):158-67. PubMed ID: 25956705
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Patients with nondysplastic Barrett's esophagus have low risks for developing dysplasia or esophageal adenocarcinoma.
    Wani S; Falk G; Hall M; Gaddam S; Wang A; Gupta N; Singh M; Singh V; Chuang KY; Boolchand V; Gavini H; Kuczynski J; Sud P; Reddymasu S; Bansal A; Rastogi A; Mathur SC; Young P; Cash B; Lieberman DA; Sampliner RE; Sharma P
    Clin Gastroenterol Hepatol; 2011 Mar; 9(3):220-7; quiz e26. PubMed ID: 21115133
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Low Risk of High-Grade Dysplasia or Esophageal Adenocarcinoma Among Patients With Barrett's Esophagus Less Than 1 cm (Irregular Z Line) Within 5 Years of Index Endoscopy.
    Thota PN; Vennalaganti P; Vennelaganti S; Young P; Gaddam S; Gupta N; Lieberman D; Sampliner R; Falk GW; Mathur S; Kennedy K; Cash BD; Moawad F; Bansal A; Spaander MC; Bruno MJ; Vargo J; Sharma P
    Gastroenterology; 2017 Apr; 152(5):987-992. PubMed ID: 27988383
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Management of low-grade dysplasia in Barrett's esophagus.
    Wani S
    Curr Opin Gastroenterol; 2012 Jul; 28(4):370-6. PubMed ID: 22508323
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Predictors of Progression in Barrett's Esophagus with Low-Grade Dysplasia: Results from a Multicenter Prospective BE Registry.
    Krishnamoorthi R; Lewis JT; Krishna M; Crews NJ; Johnson ML; Dierkhising RA; Ginos BF; Wang KK; Wolfsen HC; Fleischer DE; Ramirez FC; Buttar NS; Katzka DA; Iyer PG
    Am J Gastroenterol; 2017 Jun; 112(6):867-873. PubMed ID: 28374813
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Efficacy and Safety of Radiofrequency Ablation vs. Endoscopic Surveillance for Barrett's Esophagus With Low-Grade Dysplasia: Meta-Analysis of Randomized Controlled Trials.
    Wang Y; Ma B; Yang S; Li W; Li P
    Front Oncol; 2022; 12():801940. PubMed ID: 35296005
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Clinical outcomes in patients with a diagnosis of "indefinite for dysplasia" in Barrett's esophagus: a multicenter cohort study.
    Sinh P; Anaparthy R; Young PE; Gaddam S; Thota P; Balasubramanian G; Singh M; Higbee AD; Wani S; Gupta N; Rastogi A; Mathur SC; Bansal A; Horwhat JD; Cash BD; Falk GW; Lieberman DA; Vargo JJ; Sampliner RE; Sharma P
    Endoscopy; 2015 Aug; 47(8):669-74. PubMed ID: 25910065
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Symptoms and endoscopic features at barrett's esophagus diagnosis: implications for neoplastic progression risk.
    Coleman HG; Bhat SK; Murray LJ; McManus DT; O'Neill OM; Gavin AT; Johnston BT
    Am J Gastroenterol; 2014 Apr; 109(4):527-34. PubMed ID: 24589668
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Healthcare Resource Utilization and Costs Among Patients With Gastroesophageal Reflux Disease, Barrett's Esophagus, and Barrett's Esophagus-Related Neoplasia in the United States.
    Sharma P; Falk GW; Bhor M; Ozbay AB; Latremouille-Viau D; Guerin A; Shi S; Elvekrog MM; Limburg P
    J Health Econ Outcomes Res; 2023; 10(1):51-58. PubMed ID: 36883055
    [No Abstract]   [Full Text] [Related]  

  • 40. Length of Barrett's esophagus in the presence of low-grade dysplasia, high-grade dysplasia, and adenocarcinoma.
    Barrie J; Yanni F; Sherif M; Dube AK; Tamhankar AP
    Surg Endosc; 2021 Aug; 35(8):4756-4762. PubMed ID: 32880012
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.